We consider estimation in a randomised placebo-controlled or standard-of-care-controlled drug trial with quantitative outcome, where participants who discontinue an investigational treatment are not followed up thereafter, and the estimand follows a treatment policy strategy for handling treatment discontinuation. Our approach is also useful in situations where participants take rescue medication or a subsequent line of therapy and the estimand follows a hypothetical strategy to estimate the effect of initially randomised treatment in the absence of rescue or other active treatment. Carpenter et al proposed reference-based imputation methods which use a reference arm to inform the distribution of post-discontinuation outcomes and hence to inform an imputation model. However, the reference-based imputation methods were not formally justified. We present a causal model which makes an explicit assumption in a potential outcomes framework about the maintained causal effect of treatment after discontinuation. We use mathematical argument and a simulation study to show that the "jump to reference", "copy reference" and "copy increments in reference" reference-based imputation methods, with the control arm as the reference arm, are special cases of the causal model with specific assumptions about the causal treatment effect. We also show that the causal model provides a flexible and transparent framework for a tipping point sensitivity analysis in which we vary the assumptions made about the causal effect of discontinued treatment. We illustrate the approach with data from two longitudinal clinical trials.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048106PMC
http://dx.doi.org/10.1080/10543406.2019.1684308DOI Listing

Publication Analysis

Top Keywords

reference-based imputation
16
imputation methods
12
causal model
12
tipping point
8
clinical trials
8
quantitative outcome
8
treatment
8
treatment discontinuation
8
reference arm
8
causal treatment
8

Similar Publications

Background: The ICH E9 (R1) addendum on Estimands and Sensitivity analysis in Clinical trials proposes a framework for the design and analysis of clinical trials aimed at improving clarity around the definition of the targeted treatment effect (the estimand) of a study.

Methods: We adopt the estimand framework in the context of a study using "trial emulation" to estimate the risk of pneumocystis pneumonia, an opportunistic disease contracted by people living with HIV and AIDS having a weakened immune system, when considering two antibiotic treatment regimes for stopping antibiotic prophylaxis treatment against this disease. A "while on treatment" strategy has been implemented for post-randomisation (intercurrent) events.

View Article and Find Full Text PDF
Article Synopsis
  • Clinical trials have shown that SGLT2 inhibitors like dapagliflozin benefit adults with diabetic and chronic kidney diseases, but their effects on younger patients, especially those with Alport syndrome, remain unclear.
  • The DOUBLE PRO-TECT Alport trial will involve participants aged 10 to 39 with a confirmed diagnosis of Alport syndrome and elevated albumin levels, testing the drug's safety and efficacy over 48 weeks compared to a placebo.
  • The study aims to measure changes in urinary albumin-to-creatinine ratio (UACR) and kidney function to determine if these inhibitors can help protect against kidney failure in young patients.
View Article and Find Full Text PDF

The ICH E9(R1) Addendum (International Council for Harmonization 2019) suggests treatment-policy as one of several strategies for addressing intercurrent events such as treatment withdrawal when defining an estimand. This strategy requires the monitoring of patients and collection of primary outcome data following termination of randomised treatment. However, when patients withdraw from a study early before completion this creates true missing data complicating the analysis.

View Article and Find Full Text PDF
Article Synopsis
  • A major challenge in spatially resolved transcriptomics (SRT) is the evaluation of computational methods, often hampered by biases in simulated data.
  • The paper introduces scCube, a Python package designed to create independent and varied simulations of SRT data while preserving spatial expression patterns of genes.
  • The effectiveness of scCube is validated against existing simulators and shown to be useful in benchmarking techniques for spot deconvolution, gene imputation, and resolution enhancement through three detailed applications.
View Article and Find Full Text PDF

Accurate frequentist performance of a method is desirable in confirmatory clinical trials, but is not sufficient on its own to justify the use of a missing data method. Reference-based conditional mean imputation, with variance estimation justified solely by its frequentist performance, has the surprising and undesirable property that the estimated variance becomes smaller the greater the number of missing observations; as explained under jump-to-reference it effectively forces the true treatment effect to be exactly zero for patients with missing data.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!